Protease-activated receptor-2 stimulates angiogenesis and accelerates hemodynamic recovery in a mouse model of hindlimb ischemia

被引:63
作者
Milia, AF
Salis, MB
Stacca, T
Pinna, A
Madeddu, P
Trevisani, M
Geppetti, P
Emanueli, C
机构
[1] INBB, Natl Lab, Cardiovasc Med & Gene Therapy Sect, I-07033 Osilo, SS, Italy
[2] Univ Sassari, I-07100 Sassari, Italy
[3] Univ Ferrara, I-44100 Ferrara, Italy
关键词
proteinase-activated receptor-2; angiogenesis; skeletal muscle; ischemia;
D O I
10.1161/01.RES.0000031958.92781.9E
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Protemase-activated receptors (PAR-2) are expressed by the cardiovascular system and mediate vasodilation, plasma protein extravasation, and endothelial cell proliferation, all regarded as essential steps for neovascularization. We investigated the angiogenic action of PAR-2 signaling in vivo. The effect of the PAR-2 activating peptide (PAR-2AP, SLIGRL-NH2) was assessed in the absence of ischemia, and the therapeutic potential of PAR-2AP and the PAR-2 agonist trypsin (at 300 and 1.5 nmol IM daily for 21 days, respectively) was also tested in mice subjected to unilateral limb ischemia. PAR-2AP increased capillarity in normoperfused adductor skeletal muscles, whereas neither the vehicle of the PAR2-AP nor the PAR-2 reverse peptide (PAR-2RP, LRGILS-NH2) did produce any effect. In addition, both PAR-2AP and trypsin enhanced reparative angiogenic response to limb ischemia, an effect that was not produced by PAR-2RP or the vehicle of PAR-2 agonists. Potentiation of reparative angiogenesis by PAR-2AP or trypsin resulted in an accelerated hemodynamic recovery and enhanced limb salvage. In conclusions, our study is the first to demonstrate the angiogenic potential of PAR-2 stimulation in vivo. If similar effects occur in humans, PAR-2AP agonists could have some therapeutic potential for the treatment of tissue ischemia.
引用
收藏
页码:346 / 352
页数:7
相关论文
共 38 条
[1]   Receptor-activating peptides distinguish thrombin receptor (PAR-1) and protease activated receptor 2 (PAR-2) mediated hemodynamic responses in vivo [J].
Cheung, WM ;
Andrade-Gordon, P ;
Derian, CK ;
Damiano, BP .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1998, 76 (01) :16-25
[2]   Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-α [J].
Chi, LQ ;
Li, Y ;
Stehno-Bittel, L ;
Gao, JJ ;
Morrison, DC ;
Stechschulte, FJ ;
Dileepan, KN .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (04) :231-240
[4]   Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo [J].
Cicala, C ;
Pinto, A ;
Bucci, M ;
Sorrentino, R ;
Walker, B ;
Harriot, P ;
Cruchley, A ;
Kapas, S ;
Howells, GL ;
Cirino, G .
CIRCULATION, 1999, 99 (19) :2590-2597
[5]   Differential expression of protease-activated receptors-1 and-2 in stromal fibroblasts of normal, benign, and malignant human tissues [J].
D'Andrea, MR ;
Derian, CK ;
Santulli, RJ ;
Andrade-Gordon, P .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) :2031-2041
[6]  
Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671
[7]   Trypsin is produced by and activates protease-activated receptor-2 in human cancer colon cells - Evidence for new autocrine loop [J].
Ducroc, R ;
Bontemps, C ;
Marazova, K ;
Devaud, H ;
Darmoul, D ;
Laburthe, M .
LIFE SCIENCES, 2002, 70 (12) :1359-1367
[8]   Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle [J].
Emanueli, C ;
Zacheo, A ;
Minasi, A ;
Chao, J ;
Chao, L ;
Salis, MB ;
Stacca, T ;
Straino, S ;
Capogrossi, MC ;
Madeddu, P .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (11) :2379-2385
[9]   Targeting kinin B1 receptor for therapeutic neovascularization [J].
Emanueli, C ;
Salis, MB ;
Stacca, T ;
Pintus, G ;
Kirchmair, R ;
Isner, JM ;
Pinna, A ;
Gaspa, L ;
Regoli, D ;
Cayla, C ;
Pesquero, JB ;
Bader, M ;
Madeddu, P .
CIRCULATION, 2002, 105 (03) :360-366
[10]   Angiogenesis gene therapy to rescue ischaemic tissues: achievements and future directions [J].
Emanueli, C ;
Madeddu, P .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 (07) :951-958